The global cord blood banking services market is projected to grow from USD 33.85 billion in 2025 to USD 49.85 billion by 2031, with a CAGR of 6.84%. Growth is driven by increasing awareness of stem cell therapies, advancements in regenerative medicine, and expanding clinical applications in treating hematological and genetic disorders. North America leads with 39.54% market share, while Asia-Pacific emerges as a high-growth region.
Revvity, Inc. (RVTY)
Common Stock · Currency in USD · XNYS
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
Company Info
SIC3826
Composite FIGIBBG000FXW512
CIK0000031791
IPOJun 1, 1972
Sectorlaboratory analytical instruments
Highlights
Market Cap$9.94B
EPS$1.60
P/E Ratio53.29
Revenue$2.84B
Gross Profit$1.50B
Net Income$186.61M
Employees11,000
WSO111,803,327
Phone781-663-6900
Websitehttps://www.revvity.com
Related Tickers
TECH
Bio-Techne Corp.
$53.13 0.00%
A
Agilent Technologies Inc.
$115.48 0.00%
TMO
Thermo Fisher Scientific, Inc.
$489.90 0.00%
MTD
Mettler-Toledo International
$1.26K 0.00%
WAT
Waters Corp
$304.24 0.00%
DHR
Danaher Corporation
$191.12 0.00%
IQV
IQVIA Holdings Inc.
$173.26 0.00%
BRKR
Bruker Corporation
$36.90 0.00%
BIO
Bio-Rad Laboratories, Inc.Class A
$279.99 0.00%
CRL
Charles River Laboratories International, Inc.
$173.89 0.00%
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Revvity, Inc., comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
Revvity, Inc. (RVTY) has returned -8.50% so far this year and -4.91% over the past 12 months. Looking at the last ten years, RVTY has achieved an annualized return of -2.59%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
RVTY
1M-8.11%
6M-4.82%
YTD-8.50%
1Y-4.91%
5Y-5.12%
10Y-2.59%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Revvity, Inc. (RVTY) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 11.93% | -5.92% | -8.85% | 0.83% | ||||||||
| 2025 | 12.19% | -10.81% | -6.16% | -11.30% | -4.71% | 8.04% | -8.65% | 3.55% | -1.99% | 6.90% | 12.78% | -5.67% |
| 2024 | -1.57% | 1.00% | -3.44% | -2.41% | 6.27% | -4.14% | 19.78% | -3.08% | 5.14% | -7.13% | -3.14% | -3.61% |
| 2023 | -0.29% | 2.30% | 3.88% | -6.22% | -6.44% | -24.60% | 6.21% | 23.21% |
Performance Indicators
The charts below present risk-adjusted performance metrics for Revvity, Inc. (RVTY) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of RVTY compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Revvity, Inc. volatility is 2.24%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Liabilities And Equity (USD) | 12.17B | 12.39B | 13.56B |
| Equity Attributable To Parent (USD) | 7.25B | 7.67B | 7.87B |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - |
| Equity (USD) | 7.25B | 7.67B | 7.87B |
| Other Non-current Liabilities (USD) | - | - | 341.82M |
| Long-term Debt (USD) | - | - | 3.90B |
| Noncurrent Liabilities (USD) | 3.59B | 4.07B | 4.24B |
| Other Current Liabilities (USD) | 1.15B | 485.64M | 1.25B |
| Accounts Payable (USD) | 185.46M | 167.46M | 204.12M |
| Current Liabilities (USD) | 1.33B | 653.10M | 1.45B |
| Liabilities (USD) | 4.92B | 4.73B | 5.69B |
| Other Non-current Assets (USD) | 7.10B | 6.92B | 7.03B |
| Intangible Assets (USD) | 2.35B | 2.64B | 3.02B |
| Fixed Assets (USD) | 479.25M | 482.22M | 509.65M |
| Noncurrent Assets (USD) | 9.93B | 10.04B | 10.56B |
| Other Current Assets (USD) | 1.86B | 1.98B | 2.57B |
| Inventory (USD) | 379.50M | 367.59M | 428.06M |
| Current Assets (USD) | 2.24B | 2.35B | 3.00B |
| Assets (USD) | 12.17B | 12.39B | 13.56B |
News and Insights
Carterra Inc. announced the launch of the Carterra Vega, an industry-first 48-channel High-Throughput Surface Plasmon Resonance (HT-SPR) platform that delivers 12-fold higher throughput than competing systems. The platform enables primary screening of large molecular libraries with high-resolution binding data, capable of screening over 20,000 small molecule interactions per day. The first unit is scheduled for shipment in Q1 2026 to a top 10 pharmaceutical company.
U.S. stock futures declined on Tuesday ahead of December CPI data release. Major indices were trading lower with the S&P 500 down 0.12% and Nasdaq 100 down 0.19%. Key stocks in focus include Alphabet (up on reaching $4 trillion market value), JPMorgan (ahead of earnings), Five9 (expanding Google Cloud partnership), Revvity (up 4.92% on earnings expectations), and Xpeng (down despite European expansion plans). Markets expect stable inflation at 2.7% annually and a 95% probability of unchanged Fed rates in January.
Wall Street extended its record-setting streak with major indices hitting all-time highs after a breakthrough in US-China trade negotiations. Trade tensions eased with potential tariff threats averted and promising discussions between diplomatic representatives.
Revvity reported Q2 earnings beating estimates but lowered fiscal year 2025 guidance due to challenging macroeconomic conditions and China's new hospital laboratory reimbursement policy, which is impacting its immunodiagnostics business.
Revvity reported Q2 2025 financial results with $720 million revenue, exceeding estimates, but experiencing margin compression and slight earnings decline due to tariff pressures and challenging market conditions.
The global CRISPR gene editing market is projected to grow from USD 4.15 billion in 2024 to USD 16.47 billion by 2034, driven by technological advancements, increasing investments, and growing applications in biotechnology and healthcare.
Global Preeclampsia Diagnostics Market to Exhibit Growth at a CAGR of ~4% by 2032 | DelveInsightpositive
The metastatic colorectal cancer clinical trial pipeline is accelerating, with over 150 pharmaceutical companies rigorously developing drugs for market entry. This indicates a positive sentiment for the industry as it aims to address the rising incidence of the disease.
The high content screening/imaging (HCS/I) market is projected to reach $5.1 billion by 2029, growing at a CAGR of 8.4%. Increasing R&D budgets and technological advances in HCS/I, such as AI integration, automation, and 3D cell models, are driving the market growth.
Infectious Disease Diagnostics Market to Reach USD 43.09 Billion by 2031 | SkyQuest Technologypositive
The global infectious disease diagnostics market is projected to reach $43.09 billion by 2031, growing at a CAGR of 8.20% during the forecast period. The market is driven by advancements in diagnostic technologies, rising cases of infectious diseases, and increased R&D funding.